T1	Participants 0 8	Adjuvant
T2	Participants 1162 1302	Therapy was well tolerated at all dose levels and schedules, with most patients (98%) experiencing mild-to-moderate constitutional symptoms.
T3	Participants 577 589	subcutaneous
